Hidrasec Za Otroke (Racecadotril)

Hidrasec Za Otroke is used to provide symptomatic relief of acute, non‑bloody diarrhea in children, helping to reduce stool frequency and volume.

• Management of watery stools associated with viral gastroenteritis in infants and young children.
• Adjunct therapy for bacterial gastroenteritis‑related diarrhea when rehydration is the primary treatment.
• Short‑term control of diarrhea caused by dietary indiscretion or mild infections.
• Supportive care during travel‑related diarrheal episodes in pediatric travelers.
• Use in conjunction with oral rehydration solutions to maintain fluid balance.
• Temporary relief for diarrhea episodes lasting less than 48 hours in children under twelve years.

• Racecadotril acts peripherally by inhibiting the enzyme enkephalinase, which normally degrades endogenous enkephalins in the intestinal mucosa. By preventing this breakdown, higher concentrations of enkephalins remain active at opioid receptors on enteric neurons, leading to reduced secretion of electrolytes and water into the lumen and a modest decrease in intestinal motility. This antiperistaltic effect helps to normalize stool consistency without affecting systemic opioid pathways.

Like many antidiarrheal agents, racecadotril may cause adverse reactions, most of which are mild and transient.

Common

• Mild abdominal discomfort or cramping.
• Nausea or occasional vomiting.
• Transient headache.
• Flatulence or increased gas.
• Loose stools may persist for a short period after treatment.
• Mild dizziness or light‑headedness, especially in dehydrated children.
• Temporary increase in thirst or dry mouth.

Serious

• Allergic skin reactions such as rash, itching, or urticaria.
• Severe abdominal pain with signs of intestinal obstruction.
• Hypersensitivity reactions including swelling of the face, lips, or tongue.
• Rare cases of pancreatitis reported in pediatric patients.
• Signs of severe dehydration despite therapy, requiring medical attention.

When using Hidrasec Za Otroke, caregivers should observe several precautions to ensure safe and effective treatment in children.

• Confirm that diarrhea is acute, non‑bloody, and not associated with high fever or severe abdominal pain before use.
• Do not exceed the recommended duration of therapy, typically not longer than 48–72 hours without medical advice.
• Ensure adequate fluid replacement with oral rehydration solutions alongside the medication.
• Avoid use in children with known hypersensitivity to racecadotril or any excipients in the formulation.
• Consult a healthcare professional if diarrhea persists, worsens, or is accompanied by blood or mucus.
• Use cautiously in children with underlying renal or hepatic impairment, as dose adjustment may be required.

Racecadotril may interact with certain medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with potent opioid agonists, as they may diminish the peripheral anti‑secretory effect of racecadotril.
• Co‑administration with drugs that significantly alter intestinal motility, such as high‑dose loperamide, which could increase the risk of constipation.

Use with caution

• Antibiotics that cause diarrhea as a side effect (e.g., clindamycin) – monitor clinical response.
• Medications metabolized by hepatic enzymes that could be inhibited or induced, potentially affecting racecadotril clearance.
• Electrolyte‑altering agents (e.g., oral rehydration solutions with high sodium) – adjust fluid therapy as needed.